Characterization of estrogen receptor–negative/progesterone receptor–positive breast cancer

• Published in: Human pathology 2015-11, Vol.46 (11), p.1776-1784
• Main Authors: Shen, Tiansheng, MD, PhD, Brandwein-Gensler, Margaret, MD, Hameed, Omar, MD, Siegal, Gene P., MD, PhD, Wei, Shi, MD, PhD
• Format: Article
• Language: English
• Subjects: African Americans; Age Factors; Aged; Breast cancer; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Clinical outcomes; Cloning; Confidence intervals; Endocrine therapy; Estrogen receptor; European Continental Ancestry Group; Female; Gene expression; Genotype & phenotype; Humans; Middle Aged; Neoplasm Recurrence, Local - metabolism; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - pathology; Pathology; Progesterone receptor; Prognosis; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Survival Rate; Tumors
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2015.07.019

Summary Despite the controversies, estrogen receptor–negative/progesterone receptor–positive (ER−/PR+) breast cancers have a reported incidence of 1% to 4%. These tumors are less well defined, and it is unclear whether ER−/PR+ represents a distinct subtype. Thus, we analyzed 5374 consecutive breast cancers to characterize the clinicopathological features of this underrecognized subset of tumors. The ER−/PR+ tumors, constituting 2.3% of the total, were mostly high grade and significantly seen in younger patients and African American women when compared with the ER+/PR+ and ER+/PR− groups, but similar to that of ER−/PR− phenotype ( P < .0001). A significantly prolonged relapse-free survival (RFS) was associated with the ER+/PR+ subtype when compared with the ER+/PR− ( P = .0002) or ER−/PR+ ( P = .0004) tumors, whereas all 3 groups showed a superior outcome to that of the ER−/PR− phenotype. In the subset of patients receiving endocrine therapy, those with ER+/PR+ tumors had a significantly prolonged RFS ( P = .001) and disease-specific survival ( P = .005) when compared with the group with an ER+/PR− phenotype, but did not significantly differ from those with ER−/PR+ tumors. No significant survival advantage was found between the ER+/PR− and ER−/PR+ tumors in any group of patients analyzed. Furthermore, a higher PR expression was associated with a favorable RFS and disease-specific survival in the patients with ER−/PR+ tumors. Therefore, the ER−/PR+ tumors demonstrate a similar, if not higher than, response rate to endocrine therapy when compared with the ER+/PR− tumors and thus are important to identify. Routine PR testing remains necessary in assisting clinical decision making in the pursuit of precision medicine.